Maxim Pharmaceuticals Announces New Scientific and Development Advisory Board.Business Editors & Health/Medical Writers BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--Feb. 6, 2003 Maxim Pharmaceuticals, Inc. (Nasdaq: MAXM)(SSE (1) An earlier full-screen editor in OS/2. (2) (Streaming SIMD Extensions) A series of additional instructions built into Pentium CPU chips for improved multimedia performance by performing mathematical operations on multiple sets of data at the : MAXM) today announced the membership of its new Scientific and Development Advisory Board (SDAB SDAB Subdivision and Development Appeal Board (Calgary, Alberta, Canada) ). The internationally recognized members of the SDAB will provide scientific and pharmaceutical development review and counsel to senior management and the Company's Board of Directors. During its meetings, the SDAB will address key top-level company strategic research and development issues. Six scientific experts will comprise the SDAB, which will be chaired by Ann Kessler, Ph.D., former Head of International Project Management, F. Hoffman-La Roche Ltd. Other SDAB members include: Roger Guillemin, M.D., a distinguished professor at The Salk Institute and recipient of the 1977 Nobel Prize Nobel Prize, award given for outstanding achievement in physics, chemistry, physiology or medicine, peace, or literature. The awards were established by the will of Alfred Nobel, who left a fund to provide annual prizes in the five areas listed above. for Medicine; Clive A. Meanwell, M.D., Ph.D., Executive Chairman and Director at The Medicines Company; John Glaspy, M.D., M.P.H., Professor of Medicine and Medical Director at the Bowyer bow·yer n. 1. One who makes or sells bows for archery. 2. Archaic An archer. Oncology Center at UCLA UCLA University of California at Los Angeles UCLA University Center for Learning Assistance (Illinois State University) UCLA University of Carrollton, TX and Lower Addison, TX ; Douglas R. Green, Ph.D., Member and Head of Cellular Immunology at the La Jolla Institute for Allergy and Immunology; and Eugene R. Schiff, M.D., Chief for the Division of Hepatology and Director for the Center for Liver Diseases at the University of Miami This article is about the university in Coral Gables, Florida. For the university in Oxford, Ohio, see Miami University. The University of Miami (also known as Miami of Florida,[2] UM,[3] or just The U School of Medicine. "We are honored and privileged to have this highly respected panel of leaders in their fields join our on-going drug development efforts in hepatitis C Hepatitis C Definition Hepatitis C is a form of liver inflammation that causes primarily a long-lasting (chronic) disease. Acute (newly developed) hepatitis C is rarely observed as the early disease is generally quite mild. and oncology," said Larry Stambaugh, Chairman, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Maxim Pharmaceuticals. "The contribution of the SDAB is expected to enrich and strengthen Maxim's path to commercialized drugs." Maxim Overview Maxim Pharmaceuticals is a global biopharmaceutical company with a diverse pipeline of therapeutic candidates for life-threatening cancers and liver diseases. Maxim's research and development programs are designed to offer hope to patients by developing safe and effective therapeutic candidates that have the potential to extend survival while maintaining quality of life. Maxim has attracted an experienced pharmaceutical management group and a team of employees dedicated to commercializing life-enhancing product candidates. Joining this motivated team in its mission are world leading scientific and clinical investigators and major pharmaceutical development partners. Maxim's lead drug Ceplene(TM), based on the naturally occurring molecule histamine, is designed to prevent or inhibit oxidative stress, thereby reversing immune suppression and protecting critical immune cells. Ceplene has been tested in 17 completed or on-going clinical trials in 19 countries, including four Phase 3 clinical trials. Ceplene is currently being tested in Phase 3 cancer clinical trials for advanced metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. melanoma and acute myelogenous leukemia acute myelogenous leukemia n. Abbr. AML Myelogenous leukemia characterized by rapid abnormal increase in the number of myeloblasts and progression of symptoms. . Phase 2 trials of Ceplene are also underway for the treatment of hepatitis C and advanced renal cell carcinoma renal cell carcinoma or hypernephroma Malignant tumour of the cells that cover and line the kidney. It usually affects persons over age 50 who have vascular disorders of the kidneys. It seldom causes pain, unless it is advanced. . More than 1,600 patients have participated in the Company's completed and on-going clinical trials. Ceplene is an investigational drug and has not been approved by the U.S. Food and Drug Administration or any international regulatory agency. Maxim is also developing small-molecule inhibitors and activators of programmed cell death pro·grammed cell death n. See apoptosis. programmed cell death proposed system of cell death, often including poly(ADP)-ribosylation, ensures that a cell will not survive if it is so badly damaged that its recovery would harm the , also known as apoptosis, which may serve as drug candidates for cancer, cardiovascular disease and other degenerative diseases. The Company's third technology platform, the MX8899 topical gel, is being tested in an attempt to help patients who suffer from oral mucositis and radiation dermatitis, both of which are side effects of certain cancer therapies. This news release contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding the efficacy, safety and intended utilization of Ceplene, the apoptosis inducers, and MX8899, and the conduct, results and timelines associated with the Company's clinical trials. Such statements are only predictions, and the Company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in larger-scale clinical trials, and the risk that the Company will not obtain approval to market its product. These factors and others are more fully discussed in the Company's periodic reports and other filings with the Securities and Exchange Commission. Note: The Maxim logo is a trademark of the Company. Editor's Note: This release is also available on the Internet at http://www.maxim.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion